Skip to main content
    P

    Processa Pharmaceuticals Inc (PCSA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.72
    -0.14 (-7.53%)

    Market Cap: $5.20M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Processa Pharmaceuticals Inc (PCSA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Processa Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$13.56M, operating cash flow was -$11.39M and free cash flow was -$11.39M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$183.16M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $13.99M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$7.81M$7.27M$5.80M$11.49M$7.44M$8.70M$2.32M$3.09M$964.16K$0
    Operating income-$13.99M-$12.05M-$11.46M-$27.53M-$12.13M-$15.14M-$3.94M-$4.52M-$1.80M$0
    Net income-$13.56M-$11.85M-$11.12M-$27.42M-$11.43M-$14.41M-$3.36M-$3.77M-$1.86M-$1.92M
    EBITDA-$13.67M-$12.05M-$11.46M-$26.62M-$11.34M-$14.13M-$3.13M-$3.83M-$1.78M$1.38K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$12.47M$0$0$0$0
    Gross profit$0$0$0-$301$0$0$0-$301$0$0$0-$140
    Operating income-$184.13M-$2.34M-$3.33M-$3.70M-$3.49M-$3.95M-$2.85M-$2.73M-$3.42M-$3.08M-$2.81M-$2.47M
    Net income-$183.16M-$3.27M-$3.38M-$3.36M-$3.44M-$3.93M-$2.83M-$2.73M-$3.38M-$3.01M-$2.73M-$2.40M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $5.54M were 70.9% of total assets of $7.81M, against total liabilities of $2.24M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$7.81M$3.23M$5.79M$8.62M$26.46M$25.21M$10.88M$12.48M$2.98M$2.36M
    Current assets$5.67M$1.88M$5.63M$8.39M$18.33M$16.20M$1.01M$2.02M$2.95M$2.34M
    Cash and equivalents$5.54M$1.19M$4.71M$6.50M$16.50M$15.42M$691.54K$1.74M$2.85M$1.07M
    Total liabilities$2.24M$1.53M$797.48K$1.15M$978.40K$2.27M$2.87M$2.78M$2.61M$97.69K
    Short-term debtN/A$73.02K$83.65K$78.90K$71.08K$117.57K$802.50K$230.00K$2.45M$0
    Long-term debtN/AN/AN/AN/AN/A$44.88K$0$0$0$0
    Shareholder equity$5.58M$1.70M$4.99M$7.47M$25.49M$22.94M$8.01M$9.70M$373.16K$2.27M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$182.01M$2.07M$4.52M$7.81M$7.58M$8.18M$4.81M$3.23M$4.94M$7.60M$9.94M$5.79M
    Total liabilities$1.86M$2.39M$1.98M$2.24M$1.75M$2.07M$1.28M$1.53M$1.22M$1.58M$1.06M$797.48K
    Cash and equivalents$180.21M$196.32K$1.69M$5.54M$6.31M$6.94M$2.90M$1.19M$2.89M$5.57M$8.92M$4.71M
    Shareholder equity-$181.38M-$317.34K$2.54M$5.58M$5.83M$6.11M$3.53M$1.70M$3.72M$6.02M$8.88M$4.99M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$11.39M-$11.25M-$8.06M-$9.61M-$8.72M-$3.14M-$2.75M-$3.71M-$1.65M-$2.16M
    Capital expenditures$0$3.24K$2.78K$0$0$4$0$20.50K$20.62K$23.77K
    Free cash flow-$11.39M-$11.25M-$8.07M-$9.61M-$8.72M-$3.14M-$2.75M-$3.73M-$1.68M-$2.18M
    Dividends paidN/AN/AN/AN/AN/A$767.25KN/A$0$0$0
    Share repurchasesN/AN/AN/A$300.00K$0N/AN/AN/AN/AN/A
    Investing cash flow-$850.00K-$3.24K-$2.78K$0$0$0$0-$22.28K$1.00M-$1.04M
    Financing cash flow$16.58M$7.73M$6.27M-$388.84K$9.80M$17.87M$1.70M$2.62M$2.43M$4.27M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.18M-$2.00M-$3.59M-$2.90M-$3.48M-$2.27M-$2.73M-$2.25M-$3.60M-$3.35M-$2.05M-$2.12M
    Capital expendituresN/AN/A$0$2$0$0$0$0$3.24K$1$4$0
    Free cash flowN/AN/A-$3.59M-$2.90M-$3.48M-$2.27M-$2.73M-$2.25M-$3.61M-$3.35M-$2.05M-$2.12M
    Last 12 quarters

    Frequently Asked Questions About PCSA

    What is Processa Pharmaceuticals' annual revenue?

    Processa Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Processa Pharmaceuticals profitable?

    No. Processa Pharmaceuticals reported net income of -$13.56M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PCSA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$11.39M minus capital expenditures of $0 produced free cash flow of -$11.39M.

    How much debt does Processa Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $5.54M.